CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls

Stefanova, 2009, Multiple system atrophy: an update, Lancet Neurol, 8, 1172, 10.1016/S1474-4422(09)70288-1

Wenning, 2013, The natural history of multiple system atrophy: a prospective European cohort study, Lancet Neurol, 12, 264, 10.1016/S1474-4422(12)70327-7

Spillantini, 1998, α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies, Proc Natl Acad Sci U S A, 95, 6469, 10.1073/pnas.95.11.6469

Aerts, 2012, CSF α-synuclein does not differentiate between parkinsonian disorders, Neurobiol Aging, 33, 10.1016/j.neurobiolaging.2010.12.001

Shi, 2011, Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression, Ann Neurol, 69, 570, 10.1002/ana.22311

Wang, 2012, Phosphorylated alpha-synuclein in Parkinson's disease, Sci Transl Med, 4, 10.1126/scitranslmed.3002566

Foulds, 2012, Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and dementia with Lewy bodies, Neurobiol Dis, 45, 188, 10.1016/j.nbd.2011.08.003

Lei, 2010, Tau protein: relevance to Parkinson's disease, Int J Biochem Cell Biol, 42, 1775, 10.1016/j.biocel.2010.07.016

Martin, 2001, Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease, JAMA, 286, 2245, 10.1001/jama.286.18.2245

Scott, 2001, Complete genomic screen in Parkinson disease: evidence for multiple genes, JAMA, 286, 2239, 10.1001/jama.286.18.2239

Duka, 2009, α-Synuclein contributes to GSK-3β-catalyzed tau phosphorylation in Parkinson's disease models, FASEB J, 23, 2820, 10.1096/fj.08-120410

Giasson, 2003, Tau and 14-3-3 in glial cytoplasmic inclusions of multiple system atrophy, Acta Neuropathol, 106, 243, 10.1007/s00401-003-0726-x

Zhou, 2006, The oxidation state of DJ-1 regulates its chaperone activity toward α-synuclein, J Mol Biol, 356, 1036, 10.1016/j.jmb.2005.12.030

Batelli, 2008, DJ-1 modulates α-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70, PLoS ONE, 3, e1884, 10.1371/journal.pone.0001884

Kilarski, 2012, Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease, Mov Disord, 27, 1522, 10.1002/mds.25132

Johnson, 2004, Tau phosphorylation in neuronal cell function and dysfunction, J Cell Sci, 117, 5721, 10.1242/jcs.01558

Ishizawa, 2003, Colocalization of tau and alpha-synuclein epitopes in Lewy bodies, J Neuropathol Exp Neurol, 62, 389, 10.1093/jnen/62.4.389

Neumann, 2004, Pathological properties of the Parkinson's disease-associated protein DJ-1 in α-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease, Acta Neuropathol, 107, 489, 10.1007/s00401-004-0834-2

Hong, 2010, DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease, Brain, 133, 713, 10.1093/brain/awq008

Waragai, 2006, Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease, Biochem Biophys Res Commun, 345, 967, 10.1016/j.bbrc.2006.05.011

Salvesen, 2012, The DJ-1 concentration in cerebrospinal fluid does not differentiate among parkinsonian syndromes, Parkinsonism Relat Disord, 18, 899, 10.1016/j.parkreldis.2012.03.013

Bandopadhyay, 2004, The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease, Brain, 127, 420, 10.1093/brain/awh054

Abdo, 2007, CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease, Neurobiol Aging, 28, 742, 10.1016/j.neurobiolaging.2006.03.010

Montine, 2010, CSF Aβ42 and tau in Parkinson's disease with cognitive impairment, Mov Disord, 25, 2682, 10.1002/mds.23287

Mollenhauer, 2009, Neurochemical biomarkers in the differential diagnosis of movement disorders, Mov Disord, 24, 1411, 10.1002/mds.22510

Alves, 2010, CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study, J Neurol Neurosurg Psychiatry, 81, 1080, 10.1136/jnnp.2009.199950

van Dijk, 2013, Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity, Eur J Neurol

Mollenhauer, 2013, Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects, Neurosci Lett, 532, 44, 10.1016/j.neulet.2012.11.004

Wennström, 2013, Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy, PLoS ONE, 8, e53250, 10.1371/journal.pone.0053250

Hall, 2012, Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders, Arch Neurol, 69, 1445, 10.1001/archneurol.2012.1654

Mollenhauer, 2011, α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study, Lancet Neurol, 10, 230, 10.1016/S1474-4422(11)70014-X

Litvan, 1997, What is the accuracy of the clinical diagnosis of multiple system atrophy?: a clinicopathologic study, Arch Neurol, 54, 937, 10.1001/archneur.1997.00550200007003